Remove Biopharma Remove Competition Remove Patients Remove Physicians
article thumbnail

HCP Engagement & Education

PM360

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. From important changes to engaging physicians to finding out how new technologies will help address HCPs education needs, hear what our specialist had to say.

article thumbnail

Three Sales Compensation Pitfalls to Avoid for a Rare Disease Product Launch

The Marketing Advantage

May 9, 2023 Since the Orphan Drug Act was passed in 1983, the number of products being researched and approved for rare and orphan diseases has increased dramatically, offering hope and life-saving treatments for the millions of patients affected by these often under-served conditions.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52
article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs. Impact for patients taking the diabetes drugs and blood thinners might be less noticeable since these drugs tend to receive coverage as preferred brand tiers with copays.

article thumbnail

Genentech’s Chief Marketing Officer Talks Marketing’s New Role and Data-Driven Content

PM360

I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content. Now, due to the highly competitive environment, the process is truncated to 12-18 months. Marketing is key to adding that layer of storytelling.

Marketing 105
article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. In January 2023, VillageMD acquired Summit Health for $8.9